All In Biotech

Drug Trial Radar · NCT06110923

A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846

A Randomized, Open-label and Parallel Study to Evaluate the Pharmacokinetics and Safety of CKD-846 in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Nov 13, 2023

Primary completion

May 10, 2024

Study completion Mar 25, 2025

Sponsor

Lead sponsor
Chong Kun Dang PharmaceuticalIndustry
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846

Conditions

  • Benign Prostate Hypertrophy(BPH)

Interventions

  • CKD-846Drug

    once administration of Investigational Product

  • D091Drug

    once administration of Investigational Product per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Concentration of CKD-846Time frame: Pre-dose, Post-dose 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 10, 24 hours (During the administration period)
  2. Concentration of D091Time frame: Pre-dose, Post-dose 0.5, 1, 2, 4, 6, 10, 24, 48, 72, 96 hours (During the administration period)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.